ArticleBMC medicine2026

Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8

Shuqing Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.